...
首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats
【24h】

Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats

机译:对大鼠Hederagenin的抗炎粥样硬化作用的实验研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The research tries to establish Wistar rat’s model of atherosclerosis for evaluating the antiatherosclerotic effect of hederagenin and exploring its antiatherosclerosis-related mechanisms. The statistical data have shown that hederagenin exhibits multiple pharmacological activities in the treatment of hyperlipidemia, antiplatelet aggregation, liver protection, and anti-inflammation, indicating that hederagenin may exert a protective effect on vascular walls by improving lipid metabolism disorders and lipid deposition. The results show that hederagenin can correct the imbalance of endothelial function by inhibiting the release of large amounts of iNOS and increasing eNOS contents and inhibits the IKKβ/NF-κB signaling pathway to reduce the release of IL-6, IFN-γ, TNF-α, and other inflammatory factors. The experimental results indicated that hederagenin can inhibit or ameliorate the pathological changes associated with AS, displaying an excellent preventive function against AS.
机译:该研究试图建立Wistar Rat的动脉粥样硬化模型,用于评估Hederagenin的抗炎症和探索其抗炎相关机制。统计数据表明,Hederagenin在治疗高脂血症,抗血小蛋白聚集,肝脏保护和抗炎中表现出多种药理活性,表明HEDeragenin通过改善脂质代谢紊乱和脂质沉积来对血管壁产生保护作用。结果表明,Hederagenin可以通过抑制大量InOS和增加enos含量的释放并抑制IKKβ/ NF-κB信号传导途径来校正内皮功能的不平衡,以减少IL-6,IFN-γ,TNF-的释放α和其他炎症因素。实验结果表明,Hederagenin可以抑制或改善与之相关的病理变化,显示出优异的预防功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号